Biden cap on drug costs will save US seniors over $1,000 a year, study finds

The annual $2,000 cap on prescription drug out-of-pocket costs applies to the Medicare programme for people age 65 or over and those with disabilities

By Reuters

  • Follow us on
  • google-news
  • whatsapp
  • telegram

Top Stories

US President Joe Biden delivers remarks during an event on Medicare drug price negotiations, in Prince George's County, Maryland, US, on August 15, 2024. — Reuters file
US President Joe Biden delivers remarks during an event on Medicare drug price negotiations, in Prince George's County, Maryland, US, on August 15, 2024. — Reuters file

Published: Thu 29 Aug 2024, 1:48 PM

Last updated: Thu 29 Aug 2024, 1:49 PM

More than one million people in the US will save over $1,000 a year beginning in 2025, when an annual $2,000 cap on prescription drug out-of-pocket costs kicks in, the leading lobbying group for older Americans said on Wednesday.

The cap, introduced as part of President Joe Biden's Inflation Reduction Act, applies to the Medicare programme for people age 65 or over and those with disabilities. Its prescription drug component, known as Part D, provides coverage for around 56 million people.


AARP, which lobbied in favour of the law, commissioned health consultancy Avalere to conduct a study on the new benefit and published a report on the findings on Wednesday.

The $2,000 cap will lower prices in 2025 for more than 3.2 million people, or around 8.4 per cent of Part D beneficiaries who do not receive other subsidies, AARP said in its report.

That represents a stark change from how Medicare Part D previously worked. Before the Inflation Reduction Act, beneficiaries who did not qualify for low income subsidies were required to pay 5 per cent of drug costs regardless of how much they had already paid.

The cap is expected to provide long-term savings, particularly for those most in need, even if Part D premiums rise next year as expected, Leigh Purvis, an AARP prescription drug pricing expert, said during a press briefing.

By 2029, the lowered cap will help 4.1 million people, or around 9.6 per cent of beneficiaries, AARP said.

The biggest impact will be felt by those who use high-priced, branded drugs the most.

Diana DiVito, 82, said the cost of the treatment she takes for chronic leukemia has averaged $858 per month over more than five years.

Her co-insurance was 33 per cent of the drug's cost until she reached the Part D cap of several thousand dollars. After that, she still had to pay 5 per cent of the drug's cost, DiVito said. In 2024, the law eliminated that additional payment.

"When I saw the first co-pay I almost had a heart attack," DiVito, an AARP member, said during the briefing. "It's a tremendous weight off my shoulders and I'm incredibly grateful."

Almost 40 per cent of people who reach the cap between 2025 and 2029, some 1.4 million, will save more than $1,000 a year, including 420,000 people, or around 12 per cent, who will save more than $3,000 annually. Currently, some patients pay over $10,000 a year, AARP said in its report.

The study excluded Part D beneficiaries who receive low income subsidies and pay nominal amounts for drugs from its analysis.

"The money seniors will no longer have to spend out-of-pocket is money they can invest in their families, broader health needs or simply save to achieve greater financial stability," AARP CEO Jo Ann Jenkins said.


More news from World